ArticleBMC cardiovascular disorders2025
Navigating the challenges of catheter ablation in patients with comorbid alcohol use disorder.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlcohol use disorder (AUD) is a significant risk factor for cardiac arrhythmias, contributing to arrhythmogenesis through direct myocardial toxicity and electrical remodeling. The present study evaluated the impact of AUD on clinical and economic outcomes following catheter ablation.
methodsThe National Inpatient Sample (2010–2019) was used to identify and analyze adults who underwent catheter ablation. Patients were stratified based on the presence of an AUD diagnosis and balanced using a 1:5 propensity score matching for demographics and comorbidities. Outcomes were assessed using logistic regression, Pearson chi-square test, and the Wilcoxon rank-sum test.
resultsAmong the 109,226 patients evaluated, 3,113 (2.85%) had AUD. The AUD cohort was younger, predominantly male, and had higher rates of smoking (40.6% vs. 16.5%), drug abuse (10.3% vs. 5.5%), and liver disease (11.3% vs. 7.8%). After matching, AUD was associated with a longer median length of stay (4.0 vs. 3.0 days, P < 0.001), higher costs ($118,427 vs. $116,503, P < 0.001), and a significantly elevated risk of gastrointestinal complications, particularly esophageal ulcers (0.4% vs. 0.1%, P = 0.006). Interestingly, in-hospital mortality was lower in the AUD group (0.6% vs. 1.4%, P < 0.001).
conclusionsThe distinct clinical profile and higher risk of specific post-ablation complications among patients with AUD reflect the need for specialized preoperative optimization. Furthermore, the paradoxically lower in-hospital mortality observed in this cohort warrants further investigation and may reflect selection bias favoring a more resilient AUD subgroup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.